Curanex Pharmaceuticals (CURX) Operating Leases (2025 - 2026)
Curanex Pharmaceuticals' (CURX) quarterly Operating Leases came in at $276359.0 in Q2 2026, up 261.48% on a YoY basis from $76452.0 in Q2 2025, and down 20.29% quarter-over-quarter from $346699.0 in Q4 2025.
Powered by 
Analysis
Curanex Pharmaceuticals (CURX) Operating Leases (2025 - 2026) Analysis & Trends
Curanex Pharmaceuticals (CURX) has reported Operating Leases for 2 consecutive years, with $276359.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Leases rose 261.48% year-over-year to $276359.0; the trailing twelve-month figure through Jun 2026 stood at $276359.0 (up 261.48% YoY), and the FY2025 full-year result was $346699.0, changed N/A from the prior year.
- Operating Leases eased to $276359.0 in Q2 2026 per CURX's latest filing, from $346699.0 in the prior quarter.
- Across five years, Operating Leases topped out at $346699.0 in Q4 2025 and bottomed at $61150.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Curanex Pharmaceuticals | 7.22 Mn | 4.28 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 276,359.00 |
| Dec 31, 2025 | 346,699.00 |
| Sep 30, 2025 | 61,150.00 |
| Jun 30, 2025 | 76,452.00 |